| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3335499 | Transfusion and Apheresis Science | 2012 | 4 Pages |
BackgroundThe benefits of fibrinogen concentrate in hypofibrinogenaemia have been established in congenital and has been used in acquired disorders. Most European countries have already changed their practice, using fibrinogen concentrate.MethodsWe compared the use of fibrinogen concentrate in acquired hypofibrinogenaemia to cryoprecipitate, which continues to be the standard of care in the UK. We undertook a retrospective analysis of fibrinogen increment in patients treated for acquired hypofibrinogenaemia.ResultsSixty four transfusion episodes receiving cryoprecipitate and 36 episodes receiving fibrinogen concentrate were compared. The median increment following 10 donor pools (two bags) of cryoprecipitate was 0.26 g/l, compared to 0.44 g/l following 2 g of fibrinogen concentrate.ConclusionWith its superior safety profile from infectious diseases, this provides further evidence to support the use of fibrinogen concentrate.
